Scientists test radiation boost with two immune drugs for tough lung cancers
NCT ID NCT04081688
Summary
This early-stage study tested whether combining two immunotherapy drugs (atezolizumab and varlilumab) with targeted radiation could help control advanced non-small cell lung cancer that had stopped responding to standard treatments. The main goal was to check if this three-part combination was safe for patients. Researchers also wanted to see if it could slow or stop the cancer's growth for a period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.